Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Lyell Immunopharma (LYEL) Assets Average (2021 - 2025)

Lyell Immunopharma's Assets Average history spans 5 years, with the latest figure at $396.7 million for Q3 2025.

  • For Q3 2025, Assets Average fell 37.69% year-over-year to $396.7 million; the TTM value through Sep 2025 reached $396.7 million, down 37.69%, while the annual FY2024 figure was $620.4 million, 26.47% down from the prior year.
  • Assets Average for Q3 2025 was $396.7 million at Lyell Immunopharma, down from $407.6 million in the prior quarter.
  • Across five years, Assets Average topped out at $1.2 billion in Q3 2021 and bottomed at $396.7 million in Q3 2025.
  • The 5-year median for Assets Average is $815.2 million (2023), against an average of $805.2 million.
  • The largest annual shift saw Assets Average dropped 17.34% in 2023 before it plummeted 39.54% in 2025.
  • A 5-year view of Assets Average shows it stood at $1.2 billion in 2021, then fell by 17.67% to $957.4 million in 2022, then decreased by 19.31% to $772.5 million in 2023, then fell by 28.15% to $555.0 million in 2024, then decreased by 28.53% to $396.7 million in 2025.
  • Per Business Quant, the three most recent readings for LYEL's Assets Average are $396.7 million (Q3 2025), $407.6 million (Q2 2025), and $460.3 million (Q1 2025).